Aquestive Therapeutics, Inc. (AQST) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Aquestive Therapeutics, Inc. (AQST) Earnings Overview
As of June 22, 2026, Aquestive Therapeutics, Inc. (AQST) reported trailing twelve-month net income of -$69M, reflecting -49.0% year-over-year growth. The company earned $-0.56 per diluted share over the past four quarters, with a net profit margin of -188.1%.
Looking at the long-term picture, AQST's historical earnings data spans multiple years. The company achieved its highest annual net income of -$8M in fiscal 2023.
Aquestive Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including DARE (-$12M net income, -1300.7% margin), AYTU (-$34M net income, -20.4% margin), PRAX (-$327M net income), AQST has outperformed on profitability metrics. Compare AQST vs DARE →
AQST Earnings vs Peers
Earnings metrics vs comparable public companies
AQST Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$84M | -89.8% | -$70M | $-0.76 | -188.1% | -156.4% |
| 2024 | -$44M | -460.8% | -$31M | $-0.51 | -76.7% | -53.5% |
| 2023 | -$8M | +85.5% | -$15M | $-0.13 | -15.6% | -29.9% |
| 2022 | -$54M | +22.9% | -$42M | $-1.12 | -114.1% | -88.2% |
| 2021 | -$71M | -26.5% | -$35M | $-1.85 | -138.8% | -68.2% |
| 2020 | -$56M | +15.8% | -$43M | $-1.66 | -121.7% | -93.6% |
| 2019 | -$66M | -7.9% | -$53M | $-2.87 | -125.9% | -100.1% |
| 2018 | -$61M | -586.3% | -$49M | $-2.96 | -91.0% | -72.6% |
| 2017 | -$9M | +6.9% | $-113,000 | $-0.45 | -13.4% | -0.2% |
| 2016 | -$10M | - | $-847,000 | $-0.39 | -18.5% | -1.6% |
Download Data
Export AQST earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AQST — Frequently Asked Questions
Quick answers to the most common questions about buying AQST stock.
What is AQST earnings per share (EPS)?
AQST trailing twelve-month (TTM) diluted EPS is $-0.56, reflecting -49.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Aquestive Therapeutics, Inc.'s net income?
Aquestive Therapeutics, Inc. (AQST) trailing twelve-month net income is $-69M as of 2025. Earnings declined -49.0% year-over-year.
Is AQST profitable?
AQST is not currently profitable on a TTM basis, reporting a net loss of $-69M. Net margin is -188.1%. Investors should monitor for a return to profitability.
What is AQST's earnings growth rate?
AQST compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are AQST's profit margins?
Aquestive Therapeutics, Inc. net profit margin is -188.1%, operating margin is -156.4%, and gross margin is +61.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is AQST growing earnings?
AQST earnings are declining — EPS fell -49.0% year-over-year. TTM net income dropped to $-69M. This contrasts with the 5-year CAGR of N/A.
What was AQST's best earnings year?
Aquestive Therapeutics, Inc.'s highest annual net income on record is $-8M, achieved in fiscal year 2023. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were AQST's earnings last quarter?
AQST's most recent reported quarter was Q1 2026. Net income was $-8M with diluted EPS of $-0.07. For a full breakdown of all quarters, see the quarterly earnings table on this page.